Company intelligence / Profile preview

Alpha BioAdvisors

Ownership: Private
Development stage: Other

Overview

Alpha BioAdvisors provides strategic advisory, valuation, and research services for the biopharma industry with expertise in emerging technologies and value creation. They do not develop their own therapeutics or have clinical results but are recognized for their proprietary methodologies in evaluating biotech assets.

Modalities: RNA interference (RNAi)mRNA-based drugsAntisense oligonucleotideMonoclonal antibodyCell therapyGene therapyCRISPR-based therapyLipid nanoparticle delivery therapyLipids & liposomes (Lipid-based therapies)Polyethylene glycol (PEG)-based therapiesRecombinant DNA (rDNA) technologyProteinPeptidesViral vector gene deliverySmall moleculeControlled/sustained release formulations
Industry: Consulting

Partnerships

Major pharmaceutical companies

Beyond the preview

Go deeper on Alpha BioAdvisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha BioAdvisors.

Explore the full profile